Vanhaesebroeck Bart, Whitehead Maria A, Piñeiro Roberto
UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6BT, UK.
J Mol Med (Berl). 2016 Jan;94(1):5-11. doi: 10.1007/s00109-015-1352-5. Epub 2015 Dec 10.
The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiology and disease. In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease. Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the aetiology and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders. The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development. In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies. The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.
PI3K脂质激酶参与信号转导和细胞内囊泡运输,赋予这些酶多种细胞功能,并在正常生理和疾病中发挥重要作用。在本综述中,我们旨在从大量关于PI3K的文献中提炼出在疾病中成功靶向该信号通路的关键相关概念。在PI3K的八种亚型中,I类PI3K与多种疾病的病因和维持有关,最显著的是癌症、过度生长综合征、炎症和自身免疫,在代谢和心血管疾病中也有潜在作用。I类PI3K抑制剂的开发主要用于癌症和炎症治疗,是药物开发中非常活跃的领域。2014年,一种PI3K p110δ亚型抑制剂被批准用于治疗特定的人类B细胞恶性肿瘤。本文总结并讨论了靶向每种I类PI3K亚型的关键治疗适应症。